Form 4: Inhibrx Biosciences CEO Buys Shares
Insider Transaction (Form 4)
Mark Lappe, Chief Executive Officer and a Director of Inhibrx Biosciences, Inc., purchased 25,000 shares of common stock on September 8, 2026.
Summary
- Open-market purchase: acquired 5,895 Common Stock at $99.29 ($585,343) on September 8, 2026; holds 711,443 after (Indirect).
- Open-market purchase: acquired 6,605 Common Stock at $100.64 ($664,719) on September 8, 2026; holds 718,048 after (Indirect).
- Open-market purchase: acquired 1,100 Common Stock at $107.12 ($117,836) on September 8, 2026; holds 719,148 after (Indirect).
- Open-market purchase: acquired 500 Common Stock at $108.23 ($54,118) on September 8, 2026; holds 719,648 after (Indirect).
- Open-market purchase: acquired 1,219 Common Stock at $111.88 ($136,382) on September 8, 2026; holds 720,867 after (Indirect).
- Open-market purchase: acquired 9,681 Common Stock at $112.28 ($1,087,001) on September 8, 2026; holds 730,548 after (Indirect).
Sentiment
Score: 9
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $2,645,399, committing personal capital to the stock.
Insider Transactions
Mark Lappe — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-08 | Open-market purchase | Common Stock | 5,895 | $99 | $585.3K | 711,443 |
| 2026-09-08 | Open-market purchase | Common Stock | 6,605 | $101 | $664.7K | 718,048 |
| 2026-09-08 | Open-market purchase | Common Stock | 1,100 | $107 | $117.8K | 719,148 |
| 2026-09-08 | Open-market purchase | Common Stock | 500 | $108 | $54.1K | 719,648 |
| 2026-09-08 | Open-market purchase | Common Stock | 1,219 | $112 | $136.4K | 720,867 |
| 2026-09-08 | Open-market purchase | Common Stock | 9,681 | $112 | $1.1M | 730,548 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-08 | Open-market purchase (5,895 shares) |
| 2026-09-08 | Open-market purchase (6,605 shares) |
| 2026-09-08 | Open-market purchase (1,100 shares) |
| 2026-09-08 | Open-market purchase (500 shares) |
| 2026-09-08 | Open-market purchase (1,219 shares) |
| 2026-09-08 | Open-market purchase (9,681 shares) |
Keywords
insider transaction, Form 4, INBX, Inhibrx Biosciences, Inc., bullish, Mark Lappe
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.